title: Long-term consequences of methamphetamine exposure in young adults are exacerbated in glial cell line-derived neurotrophic factor heterozygous mice.
abstract: Methamphetamine abuse in young adults has long-term deleterious effects on brain function that are associated with damage to monoaminergic neurons. Administration of glial cell line-derived neurotrophic factor (GDNF) protects dopamine neurons from the toxic effects of methamphetamine in animal models. Therefore, we hypothesized that a partial GDNF gene deletion would increase the susceptibility of mice to methamphetamine neurotoxicity during young adulthood and possibly increase age-related deterioration of behavior and dopamine function. Two weeks after a methamphetamine binge (4 x 10 mg/kg, i.p., at 2 h intervals), GDNF(+/-) mice had a significantly greater reduction of tyrosine hydroxylase immunoreactivity in the medial striatum, a proportionally greater depletion of dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) levels in the striatum, and a greater increase in activated microglia in the substantia nigra than wild-type mice. At 12 months of age, methamphetamine-treated GDNF(+/-) mice exhibited less motor activity and lower levels of tyrosine hydroxylase-immunoreactivity, dopamine, DOPAC, and serotonin than wild-type mice. Greater striatal dopamine transporter activity in GDNF(+/-) mice may underlie their differential response to methamphetamine. These data suggest the possibility that methamphetamine use in young adults, when combined with lower levels of GDNF throughout life, may precipitate the appearance of parkinsonian-like behaviors during aging.
authors: Department of Neurosciences and Center on Aging, Medical University of South Carolina, South Carolina 29425, USA.
authors: Heather A
authors: HA
authors: Boger
authors: Lawrence D
authors: LD
authors: Middaugh
authors: Kennerly S
authors: KS
authors: Patrick
authors: Sammanda
authors: S
authors: Ramamoorthy
authors: Emily D
authors: ED
authors: Denehy
authors: Haojie
authors: H
authors: Zhu
authors: Alejandra M
authors: AM
authors: Pacchioni
authors: Ann-Charlotte
authors: AC
authors: Granholm
authors: Jacqueline F
authors: JF
authors: McGinty
mesh_terms: D000367:Age Factors; D000704:Analysis of Variance; D000818:Animals; D000831:Animals, Newborn; D001522:Behavior, Animal / Q000187:drug effects*; D001831:Body Temperature / Q000187:drug effects; D000697:Central Nervous System Stimulants / Q000097:blood / Q000494:pharmacology*; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism; D005786:Gene Expression Regulation / Q000187:drug effects / Q000502:physiology; D051100:Glial Cell Line-Derived Neurotrophic Factor / Q000172:deficiency / Q000502:physiology*; D008694:Methamphetamine / Q000097:blood / Q000494:pharmacology*; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D017628:Microglia / Q000187:drug effects / Q000502:physiology; D009043:Motor Activity / Q000187:drug effects / Q000235:genetics; D012701:Serotonin / Q000378:metabolism; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
chemical_list: D000697:Central Nervous System Stimulants; D051100:Glial Cell Line-Derived Neurotrophic Factor; D012701:Serotonin; D008694:Methamphetamine; D014446:Tyrosine 3-Monooxygenase; D004298:Dopamine
references: Science. 2000 Oct 27;290(5492):767-73
references: 11052933
references: Neurosci Biobehav Rev. 2000 Aug;24(6):655-68
references: 10940440
references: Brain Res. 2001 Feb 9;891(1-2):228-35
references: 11164827
references: Am J Psychiatry. 2001 Mar;158(3):377-82
references: 11229977
references: Physiol Behav. 2002 Nov;77(2-3):371-85
references: 12419414
references: Ann Neurol. 2003;53 Suppl 3:S110-8; discussion S118-9
references: 12666103
references: Cell Transplant. 2003;12(3):291-303
references: 12797383
references: J Pharmacol Sci. 2003 Jul;92(3):178-95
references: 12890883
references: Am J Psychiatry. 2004 Feb;161(2):242-8
references: 14754772
references: Synapse. 2004 Apr;52(1):11-9
references: 14755628
references: J Neurosci. 2004 Dec 15;24(50):11449-56
references: 15601951
references: J Neurosci. 2005 Jan 5;25(1):29-41
references: 15634764
references: Brain Res. 2005 Feb 9;1034(1-2):153-61
references: 15713267
references: Neuropharmacology. 2005 Mar;48(3):391-7
references: 15721171
references: Brain Res. 2005 Jul 12;1049(2):171-81
references: 16043139
references: Brain Res. 2006 Jan 19;1069(1):104-12
references: 16380100
references: Exp Neurol. 2006 Dec;202(2):336-47
references: 16889771
references: Eur Neuropsychopharmacol. 2004 Mar;14(2):93-104
references: 15013024
references: Exp Neurol. 2004 May;187(1):47-57
references: 15081587
references: J Pharmacol Exp Ther. 2004 May;309(2):578-86
references: 14747615
references: Trends Neurosci. 2004 Aug;27(8):468-74
references: 15271494
references: Neurosci Lett. 2004 Sep 9;367(3):349-54
references: 15337264
references: J Pharmacol Exp Ther. 2004 Oct;311(1):1-7
references: 15163680
references: Brain Res. 1980 Jan 6;181(1):151-60
references: 7350950
references: Eur J Pharmacol. 1980 Aug 29;66(2-3):201-5
references: 6108224
references: Neuropharmacology. 1981 Dec;20(12A):1135-40
references: 6172742
references: Brain Res Bull. 1983 Sep;11(3):309-14
references: 6640361
references: Brain Res. 1982 Mar 4;235(1):93-103
references: 6145488
references: Nature. 1984 Oct 4-10;311(5985):461-4
references: 6207434
references: Science. 1989 Jan 20;243(4889):398-400
references: 2563176
references: Neuroscience. 1989;29(3):503-37
references: 2472578
references: J Comp Neurol. 1989 Sep 15;287(3):357-72
references: 2570793
references: Psychopharmacology (Berl). 1991;103(1):41-5
references: 1826059
references: J Pharmacol Exp Ther. 1992 Feb;260(2):817-24
references: 1346646
references: Ann N Y Acad Sci. 1992 May 11;648:229-38
references: 1637048
references: Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):7095-9
references: 1353885
references: Science. 1993 May 21;260(5111):1130-2
references: 8493557
references: J Pharmacol Exp Ther. 1994 Aug;270(2):741-51
references: 8071867
references: J Neurosci. 1995 Mar;15(3 Pt 1):1714-23
references: 7534339
references: Neurotoxicol Teratol. 1995 Jan-Feb;17(1):7-12
references: 7535890
references: J Comp Neurol. 1995 May 15;355(4):479-89
references: 7636027
references: Nature. 1996 Jul 4;382(6586):73-6
references: 8657307
references: Nature. 1996 Jul 4;382(6586):76-9
references: 8657308
references: Neurodegeneration. 1996 Jun;5(2):137-43
references: 8819134
references: J Neural Transm Suppl. 1995;46:209-16
references: 8821057
references: J Neurosci. 1996 Dec 15;16(24):8132-9
references: 8987838
references: Synapse. 1997 May;26(1):81-92
references: 9097408
references: Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):14083-8
references: 9391156
references: Brain Res. 1998 Jun 22;797(1):42-54
references: 9630504
references: Ann Neurol. 1998 Jul;44(1):143-7
references: 9667606
references: Ann Neurol. 1998 Sep;44(3 Suppl 1):S72-84
references: 9749577
references: J Pharmacol Exp Ther. 1998 Oct;287(1):107-14
references: 9765328
references: J Comp Neurol. 1998 Nov 16;401(2):253-65
references: 9822152
references: J Neurosci. 1999 Feb 15;19(4):1416-23
references: 9952418
references: J Neurosci. 1999 Feb 15;19(4):1484-91
references: 9952424
references: Neuroscience. 1999 Jan;88(2):549-59
references: 10197774
references: Ann Neurol. 1999 Oct;46(4):598-605
references: 10514096
references: Synapse. 2000 Mar 15;35(4):243-9
references: 10657033
references: J Neurosci. 2000 May 1;20(9):3182-90
references: 10777782
references: Neuroscience. 2000;101(3):607-17
references: 11113310